Project Grant R21CA283514

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $229,309.00 to The University of Texas MD Anderson Cancer Center to conduct research examining the role of the NONO pathway in the innate immune response against oncolytic adenoviruses. The award period runs from December 16, 2024 to November 30, 2026. The research aims to build on recent clinical trials of oncolytic viruses in brain tumor patients, which have shown that a small percentage of patients experience prolonged survival. The project will investigate the NONO pathway's influence on the innate immune system's response to oncolytic adenoviruses, with the goal of improving the effectiveness of these experimental cancer therapies. The University of Texas MD Anderson Cancer Center, a comprehensive cancer research and treatment center, will be conducting this study at their facilities in Houston, Texas.